SMS Pharma Q3FY26 Monitoring Report: ₹114.30 Cr Proceeds Utilized, No Deviation Noted
SMS Pharmaceuticals Limited's Q3FY26 monitoring report shows ₹114.30 crore raised via warrants. As of Dec 31, 2025, ₹80.93 crore utilized, ₹33.37 crore unutilized. No deviations from objects or finance means. Capex, working capital, and GCP expenses were reported for the quarter.
This is a standard regulatory filing detailing the utilization of previously raised funds. It does not introduce new business developments, financial results, or strategic changes that would significantly impact the company's valuation or operations.
The report is a routine monitoring update confirming utilization of funds as per the offer document with no deviations. It does not contain any new positive or negative financial information.
SMS Pharmaceuticals Limited has submitted the Monitoring Agency Report from CARE Ratings Limited concerning the utilization of proceeds from its preferential issue of convertible warrants. The report covers the quarter ended December 31, 2025.
The company had raised ₹114.30 crore through this issue. As of December 31, 2025, ₹80.93 crore has been utilized, with ₹33.37 crore unutilized. The utilization is in line with the objects disclosed in the offer document, with no material deviations noted in the objects or the means of finance. Shareholder approval for any deviations was also not required as none occurred.
During the quarter (Q3FY26), ₹30.91 crore was utilized towards capital expenditure, with payments to vendors routed through the Monitoring Agency (MA) account. Additionally, ₹15.00 crore was transferred from the MA account for working capital requirements, and ₹6.45 crore was utilized for registration and maintenance of the corporate building under General Corporate Purposes (GCP).
The unutilized proceeds are either held in the monitoring account (₹0.03 crore) or temporarily deployed towards working capital requirements (₹33.34 crore). The offer document allows for interim use of issue proceeds for temporary working capital deployment. The company has provided purchase orders on a sample basis for advance payments made towards Capex.
The completion timelines for the objects are ongoing, with the outer timeline being two years from the receipt of funds. No significant delays have been reported.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.